Skip to main content
SpringerLink
Log in

Treatment Overview

  • Chapter
  • First Online:
Renal Cell Carcinoma

Abstract

Treatment strategy for patients with renal cell carcinoma (RCC) has dramatically changed during the last decades. As for the surgical treatment option, development of the laparoscopic procedure provides a great benefit for patients in terms of less invasive surgery, allowing quick recovery from the procedure. More recently, robotic surgery has been spreading and replacing the conventional laparoscopic procedure. Even more patients can be safely treated with robotic procedure. Partial nephrectomy has been reported to reduce the risk of new onset of development to chronic kidney disease and has been increasingly replacing the use of radical nephrectomy. Previously, RCC had been a contraindication for the use of tumor biopsy, but recent studies now indicate the safety of biopsy. Thus, the use of percutaneous biopsy for small renal masses is increasing, eliminating unnecessary surgery for patients with benign tumors. As for systemic therapy, introduction of targeted therapy has prolonged the survival of patients with metastatic RCC compared to that of the cytokine era. In addition, immune checkpoint inhibitors have recently introduced a major paradigm shift in sequential therapy. These treatments have been supported by a great deal of evidence. We need to heed the standard care recommended by guideline, but minor modifications are also required according to patient conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG (2009) Guideline for management of the clinical T1 renal mass. J Urol 182 (4):1271–1279. doi:S0022-5347(09)01728-5 [pii] 10.1016/j.juro.2009.07.004 [doi]

    Google Scholar 

  2. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58(3):398–406. doi:10.1016/j.eururo.2010.06.032

    Article  PubMed  Google Scholar 

  3. National Comprehensive Cancer Network (2014) Kidney cancer. NCCN Clinical Practice Guideline in Oncology (NCCN GuidelinesTM) Version 1

    Google Scholar 

  4. Campbell SC, Lane BR (eds) (2012) Malignant renal tumors. Campbell-Walsh urology. Elsevier, Philadelphia

    Google Scholar 

  5. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101(3):297–301

    CAS  PubMed  Google Scholar 

  6. Weight CJ, Kim SP, Lohse CM, Cheville JC, Thompson RH, Boorjian SA, Leibovich BC (2011) Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. Eur Urol 60(3):458–464. doi:10.1016/j.eururo.2011.04.022

    Article  PubMed  Google Scholar 

  7. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, Sylvester R (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881 Editorial by Urs E. Studer and Frederic D. Birkhauser on pp x-y of this issue. Eur Urol 55(1):28–34

    Article  PubMed  Google Scholar 

  8. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT, Russo P (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7(9):735–740. doi:10.1016/S1470-2045(06)70803-8

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI (2012) A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol 61(4):735–731. doi:10.1016/j.eururo.2011.11.047

    Google Scholar 

  10. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P (2009) Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? J Urol 181(1):55–61 . doi:10.1016/j.juro.2008.09.017discussion 61-52

    Article  PubMed  Google Scholar 

  11. Novick AC, Streem S, Montie JE, Pontes JE, Siegel S, Montague DK, Goormastic M (1989) Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 141(4):835–839

    CAS  PubMed  Google Scholar 

  12. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H (2000) Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 75(12):1236–1242

    Article  CAS  PubMed  Google Scholar 

  13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305

    Article  CAS  PubMed  Google Scholar 

  14. Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115(7):1465–1471. doi:10.1002/cncr.24035

    Article  PubMed  Google Scholar 

  15. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC (2012) Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 307(15):1629–1635. doi:10.1001/jama.2012.475

    Article  CAS  PubMed  Google Scholar 

  16. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R (2011) A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59(4):543–552. doi:10.1016/j.eururo.2010.12.013

    Article  PubMed  Google Scholar 

  17. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H (2014) Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 65(2):372–377. doi:10.1016/j.eururo.2013.06.044

    Article  PubMed  Google Scholar 

  18. Amano H, Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Shimada K, Nakazawa H, Ito F, Tanabe K (2010) Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients. Int J Urol 17(7):615–622. doi:10.1111/j.1442-2042.2010.02541.x

    Article  PubMed  Google Scholar 

  19. McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P (2002) Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 60(6):1003–1009

    Article  PubMed  Google Scholar 

  20. Pahernik S, Roos F, Hampel C, Gillitzer R, Melchior SW, Thüroff JW (2006) Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience. J Urol 175(6):2027–2031. doi:10.1016/s0022-5347(06)00271-0

    Article  PubMed  Google Scholar 

  21. Maru S, Abe T, Shinohara N, Sazawa A, Maruyama S, Harabayashi T, Suzuki S, Nonomura K (2012) Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study. Int J Urol 19(2):110–116. doi:10.1111/j.1442-2042.2011.02913.x

    Article  CAS  PubMed  Google Scholar 

  22. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann M, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Staehler M, Volpe A (2013) Guidelines on renal cell carcinoma. EAU guidelines 2012 edition. European Association of Urology, Arnhem

    Google Scholar 

  23. National Comprehensive Cancer Network (2016) Kidney cancer: NCCN Clinical Practice Guideline in Oncology (NCN GuidelineTM) Version 3.2016. National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed 5 Sep 2016

  24. Peycelon M, Hupertan V, Comperat E, Renard-Penna R, Vaessen C, Conort P, Bitker MO, Chartier-Kastler E, Richard F, Roupret M (2009) Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 181(1):35–41 doi:S0022-5347(08)02445-2 [pii] 10.1016/j.juro.2008.09.025 [doi]

    Article  PubMed  Google Scholar 

  25. Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC, Kaouk JH, Klein EA, Novick AC (2010) Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol 183(4):1317–1323 doi:S0022-5347(09)03194-2 [pii] 10.1016/j.juro.2009.12.030 [doi]

    Article  PubMed  Google Scholar 

  26. Iizuka J, Kondo T, Hashimoto Y, Kobayashi H, Ikezawa E, Takagi T, Omae K, Tanabe K (2012) Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma. Int J Urol 19(11):980–986. doi:10.1111/j.1442-2042.2012.03085.x

    Article  PubMed  Google Scholar 

  27. Weight CJ, Larson BT, Gao T, Campbell SC, Lane BR, Kaouk JH, Gill IS, Klein EA, Fergany AF (2010) Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 76(3):631–637. doi:10.1016/j.urology.2009.11.087

    Article  PubMed  Google Scholar 

  28. Gohji K, Hara I, Gotoh A, Eto H, Miyake H, Sugiyama T, Okada H, Arakawa S, Kamidono S (1998) Multifocal renal cell carcinoma in Japanese patients with tumors with maximal diameters of 50 mm. or less. J Urol 159(4):1144–1147

    Article  CAS  PubMed  Google Scholar 

  29. Zucchi A, Mearini L, Mearini E, Costantini E, Vivacqua C, Porena M (2003) Renal cell carcinoma: histological findings on surgical margins after nephron sparing surgery. J Urol 169(3):905–908

    Article  CAS  PubMed  Google Scholar 

  30. Castilla EA, Liou LS, Abrahams NA, Fergany A, Rybicki LA, Myles J, Novick AC (2002) Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 60(6):993–997

    Article  PubMed  Google Scholar 

  31. Campbell SC, Lane BR (2012) Malignant renal tumors. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh urology, 10th edn. Saunders, New York, pp 1413–1474

    Google Scholar 

  32. Carini M, Minervini A, Lapini A, Masieri L, Serni S (2006) Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: progression and long-term survival. J Urol 175(6):2022–2026; discussion 2026. doi:10.1016/S0022–5347(06)00275-8

    Google Scholar 

  33. Carini M, Minervini A, Masieri L, Lapini A, Serni S (2006) Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol 50(6):1263–1268; discussion 1269–1271. doi:10.1016/j.eururo.2006.05.022

    Google Scholar 

  34. Minervini A, Ficarra V, Rocco F, Antonelli A, Bertini R, Carmignani G, Cosciani Cunico S, Fontana D, Longo N, Martorana G, Mirone V, Morgia G, Novara G, Roscigno M, Schiavina R, Serni S, Simeone C, Simonato A, Siracusano S, Volpe A, Zattoni F, Zucchi A, Carini M (2011) Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. J Urol 185(5):1604–1610. doi:10.1016/j.juro.2010.12.048

    Article  PubMed  Google Scholar 

  35. Takagi T, Kondo T, Iizuka J, Kobayashi H, Hashimoto Y, Nakazawa H, Ito F, Tanabe K (2011) Postoperative renal function after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease: a comparison with radical nephrectomy. Int J Urol 18(6):472–476. doi:10.1111/j.1442-2042.2011.02765.x

    Article  PubMed  Google Scholar 

  36. Nguyen MM, Gill IS (2008) Halving ischemia time during laparoscopic partial nephrectomy. J Urol 179(2):627–632; discussion 632. doi:S0022–5347(07)02588–8 [pii] 10.1016/j.juro.2007.09.086 [doi]

    Google Scholar 

  37. Gill IS, Kamoi K, Aron M, Desai MM (2010) 800 Laparoscopic partial nephrectomies: a single surgeon series. J Urol 183(1):34–41. doi:10.1016/j.juro.2009.08.114

    Article  PubMed  Google Scholar 

  38. Patel HD, Mullins JK, Pierorazio PM, Jayram G, Cohen JE, Matlaga BR, Allaf ME (2013) Trends in renal surgery: robotic technology is associated with increased use of partial nephrectomy. J Urol 189(4):1229–1235. doi:10.1016/j.juro.2012.10.024

    Article  PubMed  Google Scholar 

  39. Aboumarzouk OM, Stein RJ, Eyraud R, Haber GP, Chlosta PL, Somani BK, Kaouk JH (2012) Robotic versus laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol 62(6):1023–1033. doi:10.1016/j.eururo.2012.06.038

    Article  PubMed  Google Scholar 

  40. Eskicorapci SY, Teber D, Schulze M, Ates M, Stock C, Rassweiler JJ (2007) Laparoscopic radical nephrectomy: the new gold standard surgical treatment for localized renal cell carcinoma. TheScientificWorldJOURNAL 7:825–836. doi:10.1100/tsw.2007.153

    Article  PubMed  Google Scholar 

  41. Borin JF (2008) Laparoscopic radical nephrectomy: long-term outcomes. Curr Opin Urol 18(2):139–144. doi:10.1097/MOU.0b013e3282f4a851

    Article  PubMed  Google Scholar 

  42. Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ (2014) Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 113(3):416–428. doi:10.1111/bju.12349

    Article  PubMed  Google Scholar 

  43. Kim EH, Tanagho YS, Bhayani SB, Saad NE, Benway BM, Figenshau RS (2013) Percutaneous cryoablation of renal masses: Washington University experience of treating 129 tumours. BJU Int 111(6):872–879. doi:10.1111/j.1464-410X.2012.11432.x

    Article  PubMed  Google Scholar 

  44. Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 179(4):1227–1233; discussion 1233–1224. doi:10.1016/j.juro.2007.11.047

    Google Scholar 

  45. Ramirez D, Ma YB, Bedir S, Antonelli JA, Cadeddu JA, Gahan JC (2014) Laparoscopic radiofrequency ablation of small renal tumors: long-term oncologic outcomes. J Endourol 28(3):330–334. doi:10.1089/end.2013.0542

    Article  PubMed  Google Scholar 

  46. Tanagho YS, Bhayani SB, Kim EH, Figenshau RS (2013) Renal cryoablation versus robot-assisted partial nephrectomy: Washington University long-term experience. J Endourol 27(12):1477–1486. doi:10.1089/end.2013.0192

    Article  PubMed  Google Scholar 

  47. Emara AM, Kommu SS, Hindley RG, Barber NJ (2014) Robot-assisted partial nephrectomy vs laparoscopic cryoablation for the small renal mass: redefining the minimally invasive ‘gold standard’. BJU Int 113(1):92–99. doi:10.1111/bju.12252

    Article  CAS  PubMed  Google Scholar 

  48. Guillotreau J, Haber GP, Autorino R, Miocinovic R, Hillyer S, Hernandez A, Laydner H, Yakoubi R, Isac W, Long JA, Stein RJ, Kaouk JH (2012) Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass. Eur Urol 61(5):899–904. doi:10.1016/j.eururo.2012.01.007

    Article  PubMed  Google Scholar 

  49. Raman JD, Raj GV, Lucas SM, Williams SK, Lauer EM, Ahrar K, Matin SF, Leveillee RJ, Cadeddu JA (2010) Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int 105(4):496–500. doi:10.1111/j.1464-410X.2009.08776.x

    Article  PubMed  Google Scholar 

  50. Kiriluk KJ, Shikanov SA, Steinberg GD, Shalhav AL, Lifshitz DA (2011) Laparoscopic partial nephrectomy versus laparoscopic ablative therapy: a comparison of surgical and functional outcomes in a matched control study. J Endourol 25(12):1867–1872. doi:10.1089/end.2011.0087

    Article  PubMed  Google Scholar 

  51. Gervais DA (2013) Cryoablation versus radiofrequency ablation for renal tumor ablation: time to reassess? J Vasc Interv Radiol JVIR 24(8):1135–1138. doi:10.1016/j.jvir.2013.05.030

    Article  PubMed  Google Scholar 

  52. El Dib R, Touma NJ, Kapoor A (2012) Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int 110(4):510–516. doi:10.1111/j.1464-410X.2011.10885.x

    Article  PubMed  Google Scholar 

  53. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431. doi:10.1016/s0022-5347(05)00148-5

    Article  PubMed  Google Scholar 

  54. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, Tanguay S, Rendon RA, Gleave ME, Drachenberg DE, Chow R, Chung H, Chin JL, Fleshner NE, Evans AJ, Gallie BL, Haider MA, Kachura JR, Kurban G, Fernandes K, Finelli A (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 60(1):39–44. doi:10.1016/j.eururo.2011.03.030

    Article  PubMed  Google Scholar 

  55. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118(4):997–1006. doi:10.1002/cncr.26369

    Article  PubMed  Google Scholar 

  56. Rais-Bahrami S, Guzzo TJ, Jarrett TW, Kavoussi LR, Allaf ME (2009) Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 103(10):1355–1358. doi:10.1111/j.1464-410X.2008.08242.x

    Article  PubMed  Google Scholar 

  57. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, Kaouk JH, Gill IS, Campbell SC (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116(13):3119–3126. doi:10.1002/cncr.25184

    Article  PubMed  Google Scholar 

  58. Gontero P, Joniau S, Oderda M, Ruutu M, Van Poppel H, Laguna MP, de la Rosette J, Kirkali Z (2013) Active surveillance for small renal tumors: have clinical concerns been addressed so far? Int J Urol 20(4):356–361. doi:10.1111/j.1442-2042.2012.03227.x

    Article  PubMed  Google Scholar 

  59. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI (2012) Treatment management of small renal masses in the 21st century: a paradigm shift. Ann Surg Oncol 9(7):2380–2387. doi:10.1245/s10434-012-2247-0

    Article  Google Scholar 

  60. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, Nogueira L, Reuter VE, Russo P (2009) Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 181(5):2033–2036. doi:10.1016/j.juro.2009.01.027

    Article  PubMed  PubMed Central  Google Scholar 

  61. Lim A, O’Neil B, Heilbrun ME, Dechet C, Lowrance WT (2012) The contemporary role of renal mass biopsy in the management of small renal tumors. Front Oncol 2:106. doi:10.3389/fonc.2012.00106

    Article  PubMed  PubMed Central  Google Scholar 

  62. Khan AA, Shergill IS, Quereshi S, Arya M, Vandal MT, Gujral SS (2007) Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists. BMC Urol 7:10. doi:10.1186/1471-2490-7-10

    Article  PubMed  PubMed Central  Google Scholar 

  63. Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, Jewett MA (2007) Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 178(2):379–386. doi:10.1016/j.juro.2007.03.131

    Article  PubMed  Google Scholar 

  64. Tsivian M, Rampersaud EN Jr, Laguna MP, Joniau S, Leveillee RJ, Shingleton WB, Aron M, Kim CY, Demarzo AM, Desai MM, Meler JD, Donovan JF, Klingler HC, Sopko DR, Madden JF, Marberger M, Ferrandino MN, Polascik TJ (2014) Small renal mass biopsy – how, what and when: report from an international consensus panel. BJU Int 113(6):854–863. doi:10.1111/bju.12470

    Article  PubMed  Google Scholar 

  65. Volpe A, Finelli A, Gill IS, Jewett MA, Martignoni G, Polascik TJ, Remzi M, Uzzo RG (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504. doi:10.1016/j.eururo.2012.05.009

    Article  PubMed  Google Scholar 

  66. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC (2008) Renal mass biopsy—a renaissance? J Urol 179(1):20–27. doi:10.1016/j.juro.2007.08.124

    Article  PubMed  Google Scholar 

  67. Herts BR, Baker ME (1995) The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol 13(4):254–261

    CAS  PubMed  Google Scholar 

  68. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C (2004) Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol 171(5):1802–1805. doi:10.1097/01.ju.0000120147.51090.2b

    Article  PubMed  Google Scholar 

  69. Long CJ, Canter DJ, Kutikov A, Li T, Simhan J, Smaldone M, Teper E, Viterbo R, Boorjian SA, Chen DY, Greenberg RE, Uzzo RG (2012) Partial nephrectomy for renal masses >/= 7 cm: technical, oncological and functional outcomes. BJU Int 109(10):1450–1456. doi:10.1111/j.1464-410X.2011.10608.x

    Article  PubMed  Google Scholar 

  70. Kopp RP, Mehrazin R, Palazzi KL, Liss MA, Jabaji R, Mirheydar HS, Lee HJ, Patel N, Elkhoury F, Patterson AL, Derweesh IH (2013) Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumors categorized by RENAL nephrometry score. BJU Int. doi:10.1111/bju.12580

    Google Scholar 

  71. Jeon SH, Kwon TG, Rha KH, Sung GT, Lee W, Lim JS, Jeong YB, Hong SH, Kim HH, Byun SS (2011) Comparison of laparoscopic versus open radical nephrectomy for large renal tumors: a retrospective analysis of multi-center results. BJU Int 107(5):817–821. doi:10.1111/j.1464-410X.2010.09688.x

    Article  PubMed  Google Scholar 

  72. Steinberg A, Finelli A, Desai M, Abreu S, Ramani A, Spaliviero M, Rybicki L, Kaouk J, Novick A, Gill I (2004) Laparoscopic radical nephrectomy for large (greater than 7 Cm, T2) renal tumors. J Urol 172(6):2172–2176. doi:10.1097/01.ju.0000140961.53335.04

    Article  PubMed  Google Scholar 

  73. Gill IS, Metcalfe C, Abreu A, Duddalwar V, Chopra S, Cunningham M, Thangathurai D, Ukimura O, Satkunasivam R, Hung A, Papalia R, Aron M, Desai M, Gallucci M (2015) Robotic level III inferior vena cava tumor thrombectomy: initial series. J Urol 194(4):929–938. doi:10.1016/j.juro.2015.03.119

    Article  PubMed  Google Scholar 

  74. Ramirez D, Maurice MJ, Cohen B, Krishnamurthi V, Haber GP (2016) Robotic level III IVC tumor thrombectomy: duplicating the open approach. Urology 90:204–207. doi:10.1016/j.urology.2016.01.011

    Article  PubMed  Google Scholar 

  75. Kalkat MS, Abedin A, Rooney S, Doherty A, Faroqui M, Wallace M, Graham TR (2008) Renal tumours with cavo-atrial extension: surgical management and outcome. Interact Cardiovasc Thorac Surg 7(6):981–985

    Article  PubMed  Google Scholar 

  76. Laird A, Choy KC, Delaney H, Cutress ML, O’Connor KM, Tolley DA, McNeill SA, Stewart GD, Riddick AC (2014) Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma. World J Urol. doi:10.1007/s00345-014-1280-y

    PubMed  Google Scholar 

  77. Weight CJ, Lythgoe C, Unnikrishnan R, Lane BR, Campbell SC, Fergany AF (2011) Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy. Urology 77(5):1142–1146. doi:10.1016/j.urology.2010.11.058

    Article  PubMed  Google Scholar 

  78. Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H (2004) A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 172(2):465–469 doi:S0022-5347(05)61660-6 [pii] 10.1097/01.ju.0000129815.91927.85 [doi]

    Article  PubMed  Google Scholar 

  79. Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59(1):18–23. doi:10.1016/j.eururo.2010.08.042

    Article  PubMed  Google Scholar 

  80. O’Malley RL, Godoy G, Kanofsky JA, Taneja SS (2009) The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 181(5):2009–2017. doi:10.1016/j.juro.2009.01.018

    Article  PubMed  Google Scholar 

  81. Kutikov A, Piotrowski ZJ, Canter DJ, Li T, Chen DY, Viterbo R, Greenberg RE, Boorjian SA, Uzzo RG (2011) Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal. J Urol 185(4):1198–1203. doi:10.1016/j.juro.2010.11.090

    Article  PubMed  PubMed Central  Google Scholar 

  82. Hinotsu S, Kawai K, Ozono S, Tsushima T, Tokuda N, Nomata K, Naito S, Akaza H (2013) Randomized controlled study of natural interferon alpha as adjuvant treatment for stage II or III renal cell carcinoma. Int J Clin Oncol 18(1):68–74. doi:10.1007/s10147-011-0345-9

    Article  CAS  PubMed  Google Scholar 

  83. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong Y-N, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016. doi:10.1016/s0140-6736(16)00559-6

    Article  CAS  PubMed  Google Scholar 

  84. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, Investigators ST (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. doi:10.1056/NEJMoa1611406

    PubMed  Google Scholar 

  85. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2007) Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109 (9):1763–1768. doi:10.1002/cncr.22600 [doi]

    Google Scholar 

  86. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659

    Article  CAS  PubMed  Google Scholar 

  87. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970

    Article  CAS  PubMed  Google Scholar 

  88. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076

    Article  PubMed  Google Scholar 

  89. Krabbe LM, Haddad AQ, Westerman ME, Margulis V (2014) Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol. doi:10.1007/s00345-014-1286-5

    PubMed  Google Scholar 

  90. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185(1):60–66. doi:10.1016/j.juro.2010.09.012

    Article  PubMed  Google Scholar 

  91. Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66(4):704–710. doi:10.1016/j.eururo.2014.05.034

    Article  PubMed  Google Scholar 

  92. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (34):5794–5799. doi:JCO.2008.21.4809 [pii] 10.1200/JCO.2008.21.4809 [doi]

    Google Scholar 

  93. Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106(9):1266–1269 doi:BJU9323 [pii] 10.1111/j.1464-410X.2010.09323.x [doi]

    Article  CAS  PubMed  Google Scholar 

  94. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882. doi:10.1002/cncr.25836

    Article  PubMed  Google Scholar 

  95. Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Tomita Y (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82(4):846–851. doi:10.1016/j.urology.2013.06.035

    Article  PubMed  Google Scholar 

  96. Tosco L, Van Poppel H, Frea B, Gregoraci G, Joniau S (2013) Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol 63(4):646–652. doi:10.1016/j.eururo.2012.09.037

    Article  PubMed  Google Scholar 

  97. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180(3):873–878; discussion 878. doi:S0022–5347(08)01226–3 [pii] 10.1016/j.juro.2008.05.006 [doi]

    Google Scholar 

  98. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296

    Article  CAS  PubMed  Google Scholar 

  99. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, Group EGW (2014) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25(Suppl 3):iii49–iii56. doi:10.1093/annonc/mdu259

  100. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  101. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590 doi:JCO.2008.20.1293 [pii] 10.1200/JCO.2008.20.1293 [doi]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111

    Article  PubMed  Google Scholar 

  103. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068. doi:JCO.2009.23.9764 [pii] 10.1200/JCO.2009.23.9764 [doi]

    Google Scholar 

  104. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281 doi:356/22/2271 [pii] 10.1056/NEJMoa066838 [doi]

    Article  CAS  PubMed  Google Scholar 

  105. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. doi:10.1038/nrc3239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104(9):3360–3365. doi:10.1073/pnas.0611533104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Hamid O, Carvajal RD (2013) Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 13(6):847–861. doi:10.1517/14712598.2013.770836

    Article  CAS  PubMed  Google Scholar 

  108. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175. doi:10.1200/JCO.2009.26.7609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. doi:10.1056/NEJMoa1510665

    Article  CAS  PubMed  Google Scholar 

  111. Carlo MI, Voss MH, Motzer RJ (2016) Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 13(7):420–431. doi:10.1038/nrurol.2016.103

    Article  CAS  PubMed  Google Scholar 

  112. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  CAS  PubMed  Google Scholar 

  113. Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E (2013) Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14(12):1233–1242. doi:10.1016/s1470-2045(13)70464-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524

    Article  CAS  PubMed  Google Scholar 

  115. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi:10.1002/cncr.25219

    Article  CAS  PubMed  Google Scholar 

  116. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939. doi:10.1016/s0140-6736(11)61613-9

    Article  CAS  PubMed  Google Scholar 

  117. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552–562. doi:10.1016/s1470-2045(13)70093-7

    Article  CAS  PubMed  Google Scholar 

  118. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, Investigators M (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814–1823. doi:10.1056/NEJMoa1510016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917–927. doi:10.1016/s1470-2045(16)30107-3

    Article  CAS  PubMed  Google Scholar 

  120. Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Lam T, Merseburger AS, Powles T, Staehler M, Volpe A, Dabestani S, Fernández-Pello Montes S, Hofmann F, Marconi L, Tahbaz R (2016) Guidelines on renal cell carcinoma. EAU guidelines 2016 edition. European Association of Urology, Arnhem

    Google Scholar 

  121. National Comprehensive Cancer Network (2016) Kidney cancer. NCCN Clinical Practice Guideline in Oncology (NCCN GuidelinesTM) Version 3

    Google Scholar 

  122. Sonpavde G, Choueiri TK (2014) Precision medicine for metastatic renal cell carcinoma. Urol Oncol 32(1):5–15. doi:10.1016/j.urolonc.2013.07.010

    Article  PubMed  Google Scholar 

  123. Zustovich F, Lombardi G, Nicoletto O, Pastorelli D (2012) Second-line therapy for refractory renal-cell carcinoma. Crit Rev Oncol Hematol 83(1):112–122. doi:10.1016/j.critrevonc.2011.08.008

    Article  PubMed  Google Scholar 

  124. Ismail S, Meskawi M, Hansen J, Bianchi M, Tian Z, Latour M, Graefen M, Montorsi F, Trinh QD, Perrotte P, Karakiewicz PI, Sun M (2014) A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. Crit Rev Oncol Hematol 90(1):49–57. doi:10.1016/j.critrevonc.2013.12.003

    Article  PubMed  Google Scholar 

  125. Motzer R, Barrios C, Kim T, Falcon S, Cosgriff T, Harker W, Pittman K, Sabbatini R, Rha S, Flaig T, Page R, Bavbek S, Beck J, Patel P, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J (2013) RECORD-3: phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. In: Annual Meeting of American Society of Clinical Oncology, Chicago

    Google Scholar 

  126. Zagoria RJ, Bechtold RE (1997) The role of imaging in staging renal adenocarcinoma. Semin Ultrasound CT MR 18(2):91–99

    Article  CAS  PubMed  Google Scholar 

  127. Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P, Brown J (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160–166. doi:10.1016/j.bone.2010.09.008

    Article  PubMed  Google Scholar 

  128. Keizman D, Ish-Shalom M, Maimon N, Gottfried M (2014) Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases? World J Urol 32(1):39–45. doi:10.1007/s00345-013-1059-6

    Article  CAS  PubMed  Google Scholar 

  129. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21(16):3150–3157. doi:10.1200/JCO.2003.04.105

    Article  CAS  PubMed  Google Scholar 

  130. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98(5):962–969

    Article  CAS  PubMed  Google Scholar 

  131. Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer 48(7):1031–1037. doi:10.1016/j.ejca.2012.02.050

    Article  CAS  PubMed  Google Scholar 

  132. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y (2009) Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218(4):530–539. doi:10.1002/path.2567

    Article  CAS  PubMed  Google Scholar 

  133. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. doi:10.1200/JCO.2010.29.7101

    Article  CAS  PubMed  Google Scholar 

  134. Fizazi K, Carducci M, Smith M, Damião R, Brown JE, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822. doi:10.1016/s0140-6736(10)62344-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132. doi:10.1200/JCO.2010.31.3304

    Article  CAS  PubMed  Google Scholar 

  136. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092. doi:10.1016/j.ejca.2012.08.002

    Article  CAS  PubMed  Google Scholar 

  137. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23(5):1341–1347. doi:10.1093/annonc/mdr435

    Article  CAS  PubMed  Google Scholar 

  138. Hunter GK, Balagamwala EH, Koyfman SA, Bledsoe T, Sheplan LJ, Reddy CA, Chao ST, Djemil T, Angelov L, Videtic GM (2012) The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol 2(4):e95–e100. doi:10.1016/j.prro.2012.01.005

    Article  PubMed  Google Scholar 

  139. Loh J, Davis ID, Martin JM, Siva S (2014) Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future oncol (Lond, Engl) 10(5):761–774. doi:10.2217/fon.14.40

    Article  CAS  Google Scholar 

  140. Lippitz B, Lindquist C, Paddick I, Peterson D, O’Neill K, Beaney R (2014) Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev 40(1):48–59. doi:10.1016/j.ctrv.2013.05.002

    Article  PubMed  Google Scholar 

  141. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225. doi:10.1016/j.prro.2011.12.004

    Article  PubMed  PubMed Central  Google Scholar 

  142. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044. doi:10.1016/s1470-2045(09)70263-3

    Article  PubMed  Google Scholar 

  143. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72. doi:10.1200/JCO.2011.41.0639

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Tsunenori Kondo M.D., Ph.D.

Authors
  1. Tsunenori Kondo M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsunenori Kondo M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Urology, Keio University School of Medicine, Tokyo, Japan

    Mototsugu Oya

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Japan KK

About this chapter

Cite this chapter

Kondo, T. (2017). Treatment Overview. In: Oya, M. (eds) Renal Cell Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55531-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55531-5_6

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55530-8

  • Online ISBN: 978-4-431-55531-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation